Serum level of IL-1ra was associated with the treatment of latent tuberculosis infection in a Chinese population.
Cytokines
Disease development
IL-1ra
Latent tuberculosis infection
Preventive treatment
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
08 May 2020
08 May 2020
Historique:
received:
11
03
2020
accepted:
21
04
2020
entrez:
10
5
2020
pubmed:
10
5
2020
medline:
11
7
2020
Statut:
epublish
Résumé
Dynamically changed levels of serum cytokines might predict the development of active TB from latent tuberculosis infection (LTBI) and monitor preventive treatment effectiveness. The aim of the study was to identify potential serum cytokines associated with LTBI treatment which might predict active disease development in a Chinese population. Based on a randomized controlled trial aiming to explore short-course regimens for LTBI treatment, the dynamic changes of serum cytokines determined by bead-based multiplex assays were investigated for the participants who developed active TB during follow-up and age and gender matched controls stayed healthy. Totally, 21 patients diagnosed with active tuberculosis (TB) during the 2-year follow-up (12 from treated groups and 9 from untreated controls) and 42 age and gender matched healthy controls (24 from treated groups and 18 from untreated controls) were included in the study. Before treatment, serum IL-1ra was statistically higher among those who developed active disease during follow-up as compared with those stayed healthy. As for treated participants, the levels of IL-1ra were significantly lower after treatment in comparison with those before treatment both in active TB group (p = 0.002) and non-TB group (p = 0.009). For untreated participants, the levels of IL-1ra were not statistically different between different time points both in active TB group (p = 0.078) and non-TB group (p = 0.265). Our results suggested that declined serum level of IL-1ra was associated with LTBI treatment. Further studies are needed to verify whether it could be used to evaluate LTBI treatment and to predict active disease development.
Sections du résumé
BACKGROUND
BACKGROUND
Dynamically changed levels of serum cytokines might predict the development of active TB from latent tuberculosis infection (LTBI) and monitor preventive treatment effectiveness. The aim of the study was to identify potential serum cytokines associated with LTBI treatment which might predict active disease development in a Chinese population.
METHODS
METHODS
Based on a randomized controlled trial aiming to explore short-course regimens for LTBI treatment, the dynamic changes of serum cytokines determined by bead-based multiplex assays were investigated for the participants who developed active TB during follow-up and age and gender matched controls stayed healthy.
RESULTS
RESULTS
Totally, 21 patients diagnosed with active tuberculosis (TB) during the 2-year follow-up (12 from treated groups and 9 from untreated controls) and 42 age and gender matched healthy controls (24 from treated groups and 18 from untreated controls) were included in the study. Before treatment, serum IL-1ra was statistically higher among those who developed active disease during follow-up as compared with those stayed healthy. As for treated participants, the levels of IL-1ra were significantly lower after treatment in comparison with those before treatment both in active TB group (p = 0.002) and non-TB group (p = 0.009). For untreated participants, the levels of IL-1ra were not statistically different between different time points both in active TB group (p = 0.078) and non-TB group (p = 0.265).
CONCLUSION
CONCLUSIONS
Our results suggested that declined serum level of IL-1ra was associated with LTBI treatment. Further studies are needed to verify whether it could be used to evaluate LTBI treatment and to predict active disease development.
Identifiants
pubmed: 32384874
doi: 10.1186/s12879-020-05047-x
pii: 10.1186/s12879-020-05047-x
pmc: PMC7206663
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
IL1RN protein, human
0
Interleukin 1 Receptor Antagonist Protein
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
330Subventions
Organisme : Program for National Natural Science Foundation of China
ID : 81702052
Références
Eur Respir J. 2018 Dec 20;52(6):
pubmed: 30361241
J Clin Rheumatol. 2007 Aug;13(4):219-20
pubmed: 17762459
Bull World Health Organ. 1982;60(4):555-64
pubmed: 6754120
Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):323-40
pubmed: 12220547
Microbes Infect. 2005 Jan;7(1):1-8
pubmed: 15716076
Korean J Intern Med. 2003 Sep;18(3):138-45
pubmed: 14619382
J Infect. 2019 Apr;78(4):292-298
pubmed: 30138640
BMC Infect Dis. 2011 May 19;11:135
pubmed: 21595874
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1044-52
pubmed: 25265362
Ann Intern Med. 2014 Sep 16;161(6):419-28
pubmed: 25111745
Respiration. 2010;80(4):275-84
pubmed: 20145387
Nat Med. 2011 Mar;17(3):372-6
pubmed: 21336285
J Immunol. 2010 Jul 1;185(1):15-22
pubmed: 20562268
Int J Tuberc Lung Dis. 2016 Nov;20(11):1554-1561
pubmed: 27776600
Cytokine Growth Factor Rev. 2013 Apr;24(2):105-13
pubmed: 23168132
Tuberculosis (Edinb). 2019 Jan;114:91-102
pubmed: 30711163
Sci Rep. 2018 Jan 18;8(1):1159
pubmed: 29348638
J Immunol. 1996 Apr 1;156(7):2503-9
pubmed: 8786311
Eur Respir J. 2011 Mar;37(3):690-711
pubmed: 20693257
Blood. 2011 Apr 7;117(14):3720-32
pubmed: 21304099
Tuberculosis (Edinb). 2011 May;91(3):250-6
pubmed: 21393062
Tuberculosis (Edinb). 2015 Dec;95(6):639-650
pubmed: 26515270
J Infect. 2017 Aug;75(2):132-145
pubmed: 28483404
Am J Respir Crit Care Med. 2015 Aug 15;192(4):485-99
pubmed: 26030187
Lancet Infect Dis. 2012 Jan;12(1):45-55
pubmed: 21846592
Am Fam Physician. 2014 Jun 1;89(11):889-96
pubmed: 25077395
Nat Microbiol. 2019 Dec;4(12):2128-2135
pubmed: 31611644
EBioMedicine. 2014 Dec 02;2(2):172-9
pubmed: 26137541
Eur Respir J. 2014 Sep;44(3):714-24
pubmed: 25063246
Int J Mycobacteriol. 2019 Jan-Mar;8(1):53-59
pubmed: 30860180
PLoS One. 2016 Apr 01;11(4):e0152483
pubmed: 27035669
Am J Respir Crit Care Med. 2015 May 15;191(10):1176-84
pubmed: 25763458